Compare · ANGO vs WST
ANGO vs WST
Side-by-side comparison of AngioDynamics Inc. (ANGO) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.85B, about 38.2x ANGO ($651.0M).
- Over the past year, ANGO is up 60.9% and WST is up 41.6% - ANGO leads by 19.4 points.
- WST has hit the wire 1 time in the past 4 weeks while ANGO has been quiet.
- WST has more recent analyst coverage (18 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- West Pharmaceutical Services Inc.
- Price
- $15.57-1.21%
- $349.86-0.85%
- Market cap
- $651.0M
- $24.85B
- 1M return
- +14.65%
- +6.55%
- 1Y return
- +60.93%
- +41.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 1
- Recent ratings
- 8
- 18
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ANGO
- SVP Quality and Regulatory Nighan Warren Jr sold $344,006 worth of shares (23,370 units at $14.72), decreasing direct ownership by 27% to 64,745 units (SEC Form 4)
- AngioDynamics to Participate in Upcoming Investor Conferences
- SVP International Piccinini Laura converted options into 8,047 shares and covered exercise/tax liability with 4,506 shares, increasing direct ownership by 5% to 81,929 units (SEC Form 4) (tax withholding)
- EVP and CFO Trowbridge Stephen A converted options into 16,296 shares and covered exercise/tax liability with 8,319 shares, increasing direct ownership by 3% to 305,796 units (SEC Form 4) (tax withholding)
- President and CEO Clemmer James C converted options into 52,358 shares and covered exercise/tax liability with 26,728 shares, increasing direct ownership by 3% to 862,448 units (SEC Form 4) (for withholding tax)
- SVP Quality and Regulatory Nighan Warren Jr converted options into 5,694 shares and covered exercise/tax liability with 1,671 shares, increasing direct ownership by 5% to 88,115 units (SEC Form 4) to satisfy withholding obligation
- SVP/GM, Vascular Access Campbell Chad Thomas converted options into 6,466 shares and covered exercise/tax liability with 2,330 shares, increasing direct ownership by 4% to 108,676 units (SEC Form 4) to satisfy withholding obligation
- Director Johnson Wesley was granted 11,887 shares, increasing direct ownership by 8% to 155,425 units (SEC Form 4)
- SVP Quality and Regulatory Nighan Warren Jr was granted 17,966 shares, increasing direct ownership by 27% to 84,092 units (SEC Form 4)
- Director Burgess Lorinda was granted 11,887 shares, increasing direct ownership by 22% to 67,144 units (SEC Form 4)
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target